Beyond The Numbers: 6 Analysts Discuss ResMed Stock
Portfolio Pulse from Benzinga Insights
Analysts' ratings for ResMed (NYSE:RMD) over the last quarter vary from bullish to bearish. The average 12-month price target for ResMed has increased by 3.09% to $222.33. Analysts have adjusted their ratings and price targets in response to market conditions and company performance.
June 25, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts' ratings for ResMed (NYSE:RMD) show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3.09% to $222.33, indicating positive expectations. Recent adjustments in ratings and price targets reflect analysts' responses to market conditions and company performance.
The increase in the average 12-month price target and the mix of bullish sentiments suggest a positive short-term outlook for ResMed. Analysts' adjustments in ratings and price targets reflect their confidence in the company's performance and market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100